@PTarantinoMD Absolutely not!!! Sorry but this is no EBM and would lead to hypes and potential arm to patients. There are scant data on ICI and Poor PS. Not to say that this approval is tvery criticisable https://t.co/HIJNDQ277G and https://t.co/pyI5puiNF0
RT @Alfdoc2: @RyanNipp @edubru @CancerCareMASCC Couldn’t agree more. We need better tool to properly assess fitness and even more now in th…
@RyanNipp @edubru @CancerCareMASCC Couldn’t agree more. We need better tool to properly assess fitness and even more now in the era of immunotherapy @gbanna74 @DralexGva https://t.co/mZHrnNQPuo
RT @Alfdoc2: Hot off press. @DralexGva @gbanna74 Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remain…
RT @Alfdoc2: Hot off press. @DralexGva @gbanna74 Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remain…
RT @DralexGva: Important unanswered question. Checkmate 817 doesn't help answer it... what is the role of IO in PS2 nsclc patients? https:/…
RT @Alfdoc2: Hot off press. @DralexGva @gbanna74 Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remain…
RT @Alfdoc2: Hot off press. @DralexGva @gbanna74 Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remain…
RT @DralexGva: Important unanswered question. Checkmate 817 doesn't help answer it... what is the role of IO in PS2 nsclc patients? https:/…
RT @Alfdoc2: Hot off press. @DralexGva @gbanna74 Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remain…
RT @DralexGva: Important unanswered question. Checkmate 817 doesn't help answer it... what is the role of IO in PS2 nsclc patients? https:/…
RT @Alfdoc2: Hot off press. @DralexGva @gbanna74 Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remain…
RT @DralexGva: Important unanswered question. Checkmate 817 doesn't help answer it... what is the role of IO in PS2 nsclc patients? https:/…
Important unanswered question. Checkmate 817 doesn't help answer it... what is the role of IO in PS2 nsclc patients?
Hot off press. @DralexGva @gbanna74 Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era. - PubMed - NCBI https://t.co/aYrobiziHn